Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1111 to 1120 of 2733 total matches.
Gedatolisib (Revtorpyk) for Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Oct 12, 2026 (Issue 1765)
: 180 mg IV on days 1, 8, and 15 of a 28-day cycle until
disease progression or unacceptable toxicity ...
The kinase inhibitor gedatolisib (Revtorpyk – Celcuity)
has been approved by the FDA for use in combination with
fulvestrant, with or without the cyclin-dependent kinase
(CDK) 4/6 inhibitor palbociclib (Ibrance), for treatment of
hormone receptor (HR)-positive, human epidermal growth
factor receptor 2 (HER2)-negative locally advanced or
metastatic breast cancer without a PIK3CA mutation in
adults who had disease progression on or after at least one
prior line of endocrine therapy for metastatic disease.
Med Lett Drugs Ther. 2026 Oct 12;68(1765):e167-8 doi:10.58347/tml.2026.1765c | Show Introduction Hide Introduction
Nebivolol (Bystolic) for Hypertension
The Medical Letter on Drugs and Therapeutics • Mar 10, 2008 (Issue 1281)
, nebivolol has nitric oxidemediated vasodilatory effects.
1
At doses of up to 10
mg, nebivolol selectively ...
Nebivolol (Bystolic - Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart failure.
Nabilone And Other Antiemetic For Cancer Patients
The Medical Letter on Drugs and Therapeutics • Jan 01, 1988 (Issue 756)
, Drugs, 30:127, 1985). Nabilone (1 or 2 mg q12h) was effective in 85% of 20
patients with nausea ...
Nabilone (Cesamet - Lilly), a synthetic cannabinoid chemically related to tetrahydrocannabinol (THC), the main active ingredient in marijuana, was recently marketed in the USA for oral treatment of nausea and vomiting associated with cancer chemotherapy. Oral THC itself, known generically as dronabinol (Marinol), is also commercially available as an antiemetic for cancer patients (Medical Letter, 27:97, 1985). Other drugs used for this purpose include metoclopramide (Reglan - Medical Letter, 24:67, 1982), prochlorperazine (Compazine; and others), haloperidol (Haldol; and others), and...
Enoxacin - A New Fluoroquinolone
The Medical Letter on Drugs and Therapeutics • Nov 13, 1992 (Issue 883)
with diminished renal function (A Fitton, Clin Pharmacokinet, 22 suppl 1:1, 1992).
The Medical Letter, Vol. 34 ...
Enoxacin (en ox' a sin; Penetrex - Rh ne-Poulenc Rorer), a fluoroquinolone antimicrobial for oral use, has now been marketed in the USA for treatment of urinary tract infections and uncomplicated urethral or cervical gonorrhea.
Sparfloxacin and Levofloxacin
The Medical Letter on Drugs and Therapeutics • Apr 25, 1997 (Issue 999)
-ACQUIRED PNEUMONIA
Drug Daily dosage Cost*
ORAL
500 mg on day 1, then 250 mg
once/day days 2-5 ...
Sparfloxacin (Zagam - Rh ne-Poulenc Rorer) and levofloxacin (Levaquin - Ortho-McNeil) are the newest fluoroquinolone antimicrobials to be approved by the US Food and Drug Administration. Sparfloxacin in a once-daily oral preparation is being marketed for treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis. Levofloxacin, which is the active stereoisomer of ofloxacin (Floxin), is available for either oral or parenteral use; it is approved for oncedaily treatment of community-acquired pneumonia, acute exacerbations of chronic bronchitis,...
Esomeprazole (Nexium)
The Medical Letter on Drugs and Therapeutics • Apr 30, 2001 (Issue 1103)
.
PROTON PUMP INHIBITORS
Drug Dosage
1
Formulation Cost
2
Esomeprazole − Nexium (AstraZeneca) 20 mg ...
Esomeprazole magnesium (Nexium - AstraZeneca), the S-isomer of omeprazole (Prilosec), is the fifth benzimidazole proton pump inhibitor to become available in the United States. Omeprazole, which was the first, is going off patent this year.
Olmesartan (Benicar) for hypertension
The Medical Letter on Drugs and Therapeutics • Aug 05, 2002 (Issue 1136)
Usual daily dosage Cost
1
Candesartan cilexetil − Atacand (AstraZeneca) 16-32 mg once $43.40 ...
Olmesartan medoxomil (Benicar - Sankyo), a substituted imidazole, is the seventh oral angiotensin II receptor blocker (ARB) approved by the FDA for treatment of hypertension.
Tests for Drugs of Abuse
The Medical Letter on Drugs and Therapeutics • Aug 19, 2002 (Issue 1137)
(DA Kidwell and FP Smith, Forensic Sci Int
2001; 116:89). Hair gives a better long-term measure (1-6 ...
Testing for drug use has become increasingly common, not only in health care, but also in drug rehabilitation, in the military, at the workplace, after accidents and in the criminal justice system. Performance-enhancing drugs such as anabolic steroids, growth hormone (Genotropin, and others) and erythropoietin (Procrit, Epogen) are not discussed here.
Treprostinil (Remodulin) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • Sep 16, 2002 (Issue 1139)
ARTERIAL HYPERTENSION
Route of Approximate
Drug administration Dosage annual cost
1
Bosentan − Tracleer ...
Treprostinil sodium (tre prost' in il; Remodulin - United Therapeutics), a prostacyclin analogue, has been approved by the FDA for continuous subcutaneous (SC) treatment of patients with pulmonary arterial hypertension who have dyspnea on more than minimal exertion (NYHA Class II-IV).
New Indications for Modafinil (Provigil)
The Medical Letter on Drugs and Therapeutics • Apr 26, 2004 (Issue 1181)
of 1.8 minutes on the Maintenance of Wakefulness
Test), but did not have a statistically significant ...
Modafinil (Provigil - Cephalon; Alertec - Draxis in Canada), first approved by the FDA in 1999 for treatment of excessive daytime sleepiness associated with narcolepsy (Medical Letter 1999; 41:30), has now also been approved for treatment of patients with excessive sleepiness due to obstructive sleep apnea/hypopnea syndrome (OSAHS) or shift work sleep disorder (SWSD) (DSM-IV, text revision, Washington, DC: American Psychiatric Association, 2000, page 622).
